BioSpace News Archive

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the United States as a therapeutic equivalent generic for Lasix ® for Injection (furosemide) approved by the U.S. Food and Drug Administration.

23andMe Holding Co. today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors.

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and financial results for the fourth quarter and year ended December 31, 2023.

Lifecore Biomedical, Inc. today announced that its Board of Directors unanimously approved the conclusion of its review of strategic alternatives that was initiated in March 2023, and, concurrently therewith, announced several strategic updates related to its operations on a stand-alone basis.

NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS”), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today a groundbreaking exclusive worldwide license agreement (the “License Agreement”) with Aexon Labs, Inc., a U.S.-based biotech firm (“Aexon”).

Alimera Sciences, Inc. announced that, pursuant to Nasdaq Listing Rule 5635 and in connection with the appointments of Mr. Todd Wood as President of U.S. Operations of the Company, Mr. Elliot Maltz as Chief Financial Officer of the Company, and five non-executive employees, the Compensation Committee of the Board of Directors of the Company approved certain inducement grants under the Alimera Sciences, Inc.

The American Diabetes Association® and The Leapfrog Group announced the first hospitals to receive national designation as Recognized Leaders in Caring for People Living with Diabetes.

Avant Technologies, Inc. today announced that it has entered into negotiations to acquire a privately held healthcare technology and data integration services firm in a cash-and-stock transaction valued at approximately $2 million.

ImpriMed today announced the company’s participation at the upcoming World Veterinary Cancer Congress (WVCC) 2024 in Tokyo, Japan, from March 21-24, 2024.

Alnylam Pharmaceuticals, Inc. announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, at the American College of Cardiology (ACC) Scientific Session on Sunday, April 7, 2024 at 7:00 pm ET.